Rani Therapeutics Holdings, Inc. (RANI)
0.86
+0.02
(+2.38%)
USD |
NASDAQ |
Aug 31, 16:00
0.86
0.00 (0.00%)
After-Hours: 20:00
Rani Therapeutics Holdings Shareholders Equity (Quarterly) : 39.23M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 39.23M |
| March 31, 2026 | 28.40M |
| December 31, 2025 | 33.01M |
| September 30, 2025 | -7.86M |
| June 30, 2025 | -5.575M |
| March 31, 2025 | -3.056M |
| December 31, 2024 | 1.992M |
| September 30, 2024 | 3.12M |
| June 30, 2024 | 2.835M |
| March 31, 2024 | 7.398M |
| December 31, 2023 | 12.87M |
| Date | Value |
|---|---|
| September 30, 2023 | 17.55M |
| June 30, 2023 | 24.09M |
| March 31, 2023 | 30.72M |
| December 31, 2022 | 36.86M |
| September 30, 2022 | 42.19M |
| June 30, 2022 | 47.81M |
| March 31, 2022 | 53.38M |
| December 31, 2021 | 47.41M |
| September 30, 2021 | 51.37M |
| June 30, 2021 | -123.67M |
| March 31, 2021 | -118.47M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 1.044M |
| CNBX Pharmaceuticals, Inc. | -2.660M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 562.20M |
| Fulcrum Therapeutics, Inc. | 310.70M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 60.84M |
| Total Liabilities (Quarterly) | 12.86M |
| Debt to Equity Ratio | 0.0905 |
| Current Ratio | 5.313 |
| Net Debt Paydown Yield | 5.17% |